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Targeted Inhibition of Histone Deacetyltransferases
for Pancreatic Cancer Therapy
R. Shane Laschanzky, Ph.D.
University of Nebraska, 2019
Supervisor: Jennifer D. Black, Ph.D.
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with a dismal five-year
survival rate of less than 10%. One major obstacle in PDAC treatment is acquired drug
resistance. Pan-histone deacetylase inhibitors (pan-HDACi) are a relatively new class of
anti-cancer drugs, with demonstrated ability to overcome drug resistance and resensitize PDAC tumors to Gemcitabine (Gem). These agents target HDACs, a family of
18 enzymes (divided into four classes, I-IV) that catalyze the deacetylation of histones
and other cellular proteins and have multiple effects on cell growth, differentiation,
survival, and tumorigenesis. Although pan-HDACi have shown significant efficacy in
preclinical analysis, and some have been FDA approved for treatment of selected
cancers, the results in clinical trials involving pancreatic cancer have been disappointing.
Pan-HDACi’s are associated with serious side effects when administered at therapeutic
doses for solid tumors, including PDAC, a limitation that is likely to account for the lack
of clinical efficacy of these agents. The toxicity of pan-HDACi is thought to reflect their
ability to inhibit multiple class I, II, and IV HDACs. With the goal of reducing this toxicity,
selective HDAC inhibitors are being developed and are undergoing preclinical and
clinical testing, with several of these agents receiving orphan drug status by the FDA.
We hypothesized that targeted inhibition of a restricted number of clinically relevant
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HDACs would recapitulate the benefits of pan-HDACi, while eliminating or greatly
reducing dose limiting toxicities.
To test this hypothesis, we initially compared the effects of pan-HDACi such as
Panobinostat with those of selective inhibitors targeting HDACs 1, 2, 3, 4, 5 and/or 6, the
HDAC proteins known to be overexpressed in PDAC. The HDAC inhibitor, Mocetinostat,
was used to selectively target HDACs 1, 2, and 3, and LMK-235 was used to inhibit
HDACs 4, 5, and 6. Mocetinostat and LMK-235 in combination demonstrated synergy in
multiple PDAC cell lines. Mocetinostat/LMK-235 also synergized with Gem to suppress
the growth/survival of PDAC cells, showing comparable synergy with that seen with the
Panobinostat/Gemcitabine combination. siRNA technology was used to identify the
specific HDAC(s), i.e., HDAC1, 2, 3, 4, 5, or 6, targeted by the combination that are
required for the observed synergy. These experiments revealed that inhibition of only
three HDAC proteins, HDACs 1, 2, and 6, is sufficient to recapitulate the antitumor
effects of pan-HDACi in PDAC cells. Notably, targeted knockdown of HDACs 1, 2, and 6
demonstrated superior synergy with Gemcitabine than the FDA approved pan-HDACi
Panobinostat, pointing to HDAC 1/2/6 inhibition and Gem as a promising combination for
PDAC treatment.
This novel approach for PDAC treatment was tested using a combination of
selective HDAC inhibitors: the HDAC 1 and 2 inhibitor, Romidepsin, and the HDAC6
inhibitors, ACY-1215 (Ricolinostat) and Nexturastat. Romidepsin is FDA approved for
the treatment of cutaneous lymphoma and ACY-1215 is currently in phase I and phase II
clinical trials for breast cancer and lymphoid malignancies. Synergy was observed with
a combination of Romidepsin and ACY-1215/Gemcitabine, and this combination showed
improved synergy compared with the Panobinostat/Gemcitabine or Mocetinostat/LMK235/Gemcitabine combinations. AnnexinV-FITC and MTT viability assays demonstrated

v
that the anti-tumor activity of the combination is partially due to an increase in apoptosis
as well as a decrease in cellular proliferation. Studies in PDAC xenograft models show
activity of the combination in vivo with no significant toxicity. Together, our results point
to targeted inhibition of HDACs 1, 2, and 6 in combination with Gemcitabine as an
effective treatment modality for PDAC, and support further research into this
combination for the management of pancreatic cancer in patients.
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The Pancreas and Pancreatic Cancer

Introduction
Despite recent advances in cancer treatment, pancreatic cancer (PaCa) remains
a deadly disease with a 5-7% five-year survival rate and a dismal 20% one-year average
survival after diagnosis [1]. Surgical resection of the pancreas with microscopically free
margins before metastasis has occurred is the only known curative treatment [2]. In
PaCa, 90% of deaths are caused by distant metastasis and over 50% of patients present
with distant metastasis at the time of diagnosis [3].
Other than family history, major predisposing factors for PaCa include: cigarette
smoking, heavy alcohol consumption, type 2 diabetes and chronic pancreatitis [4]. Cost
effective, non-invasive, accurate screening tools for PaCa are not currently available.
PaCa is typically discovered late in the disease when patients present with asthenia,
anorexia, weight loss, icterus and abdominal pain [5]. Given that patients presenting
with advanced disease are not candidates for surgical resection, chemotherapy remains
the best therapeutic option.

Pancreas – Structure/Function
The pancreas, which has been compared to a tadpole in shape, consists of a
head, neck, body and tail. This spongy pinkish-grey gland is approximately six inches
long and located posterior to the stomach, with the pancreatic head resting in the curve
of the duodenum. The body and the tail of the pancreas curve around and end near the
splenic hilum [6]. Although probably best characterized as an insulin and glucagon
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secreting endocrine gland, the pancreas serves both an endocrine and an exocrine
function, secreting both hormones and digestive enzymes.
The endocrine tasks of the pancreas are carried out by a cluster of α, β, δ, and
pancreatic polypeptide (PP) cells, collectively referred to as the “Islets of Langerhans”
[7]. These clusters act as master regulators of blood glucose levels and contribute to
energy metabolism through the secretion of insulin, glucagon, somatostatin, and
pancreatic polypeptide [8].
The majority of the pancreas consists of exocrine pancreatic tissue [9]. The
exocrine functions of the pancreas are carried out by two major cell types: ductal and
acinar. The acinar cells produce digestive enzyme precursors called zymogens [8]. The
zymogen precursors eventually constitute lipase, protease and amylase. These three
enzymes act to help digest fat, protein, and carbohydrates [6]. The approximately 240
mL of digestive juice produced daily by the acinar cells are carried to the digestive
system through an intricate system of ducts comprised of specialized pancreatic
epithelial cells [6].
The pancreatic juice is delivered to the duodenum and eventually the digestive
system via one of two major pancreatic ducts: the duct of Wirsung (major) and the duct
of Santorini (minor) [9]. In addition to facilitating delivery of digestive enzymes, the
ductal cells secrete bicarbonate to neutralize stomach acidity [10]. Interestingly,
although 90% of new PaCa cases are classified as ductal [6] the cell of origin for
Pancreatic Ductal Adenocarcinoma (PDAC) may not be ductal in origin. Acinar, ductal
or islet cells have all been hypothesized as the progenitor of PDAC with the debate
ongoing [11].

PDAC ranks among the deadliest of cancers and is the 4th leading

cause of cancer-related deaths worldwide. PDAC’s high mortality rate can, in part, be
attributed to its ability to resist chemotherapy. PDAC ranks among the highest of the
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chemo-resistant cancers [2]. The research described in this dissertation will focus solely
on PDAC.

Transformation to Cancer
PDAC exhibits a high degree of complexity; on average PDAC tumors carry 63
genetic alterations in 12 core signaling pathways [12]. An abundance of research has
been done on the pathways pancreatic cells take on their transformation into cancer.
Despite the mutational heterogeneity between individual PDAC tumors, the progression
from normal epithelia to dysplasia, and finally to invasive cancer is commonly linked to
well-characterized genetic mutations. The overwhelming majority of PDAC tumors
contain genetic alterations of at least one of four genes: KRAS2, CDKN2, TP53, and
SMAD4 [9].
Mutation of the KRAS2, CDKN2, TP53, and SMAD4 genes is thought to occur in
a stepwise manner, with tumor development beginning with KRAS2 activation and
CDKN2 abrogation, followed by TP53 and SMAD4 mutation or downregulation. KRAS2
is a form of constitutively active RAS that acts to lock the cell in a perpetually
proliferative state [13]. The importance of the KRAS mutation to pancreatic
tumorigenesis is manifest by its presence in 90-99% of PDAC tumors [13, 14].
Abrogation of the tumor-suppressor gene CDKN2, which encodes the protein p16, is
also highly prevalent, occurring in 95% of PDAC [14]. p16 protein promotes the G1-S
checkpoint of the cell cycle and loss of p16 contributes to unregulated growth [15].
Pancreatic ductal cells next gain the ability to bypass DNA damage checkpoints
and apoptotic signals via mutations in TP53 [16]. TP53 mutations/deletions are found in
up to 75% of PDAC [14]. Mutations in SMAD4, which is altered in approximately 55% of
PDAC, are believed to arise late in tumor development and promote an invasive
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phenotype by contributing to epithelial-to-mesenchymal transition (EMT) and further
dysregulation of extracellular signaling mechanisms [17].

Tumor Microenvironment
The genetic alterations in PDAC give rise to a highly complex tumor
microenvironment. Pancreas primary tumors are characteristically dense, hypoxic, and
acidic [18]. PDAC stroma, which consists of cellular and acellular components, is
typically so abundant as to constitute the majority of the primary tumor [18].
The cellular component of the stroma consists of: endothelial cells, cancerassociated fibroblasts (CAFs), pancreatic stellate cells (PSCs), infiltrating immune and
inflammatory cells, as well as nervous tissue and adipocytes [19]. Quiescent PSCs are
credited with giving rise to CAFs [20]. CAFs play a central role in malignancy; they are
important for the establishment of an immunosuppressive microenvironment through
secretion of growth factors and cytokines, which in turn promote tumor growth,
metastasis and chemoresistance [19].
The acellular component or extracellular matrix (commonly referred to as
desmoplasia) consists of: hyaluronan, collagen fibers, fibronectin, proteoglycans,
hyaluronic acid, as well as growth factors, cytokines, proteinases and other enzymes
[18]. PSCs secrete collagen and other components of the extracellular matrix in
response to growth factors, such as, TGFβ1 and platelet-derived growth factor (PDGF)
[21]. Interestingly, PSCs also regulate the reabsorption and turnover of the ECM via
secretion of metalloproteinases [22].
In addition to the general sparsity of vasculature in PDAC stroma, the ECM
creates a physical barrier to drug delivery via constriction of the intratumoral microvessels [23]. Interestingly, although there is an abundance of evidence of stromal
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involvement in drug resistance and tumor promotion [24], multiple studies have
demonstrated that therapeutic depletion of the ECM does more harm than good, with
ablation of PSCs and CAFs accelerating metastasis and reducing survival in PaCa
mouse models [25-27].

Current First-Line Chemotherapy Options
Currently, PDAC is treated by one of two first line therapies: FOLFIRINOX, or a
combination of gemcitabine and Abraxane [2].
Gemcitabine (Gem) is a synthetic pyrimidine nucleoside prodrug, a nucleoside
analog in which the hydrogen atoms on the 2’ carbon of deoxycytidine are replaced by
fluorine atoms. Considered an anti-metabolite because of its ability to become
incorporated into DNA and halt replication, Gem was originally approved as a single firstline agent for PDAC therapy [28]. Additionally, Gem is demonstrated to be a nucleoside
metabolic inhibitor with the mechanism of action being to abrogate nucleic acid synthesis
[29]. Typically, patients are treated with Gem via slow-drip intravenous injection at 1000
mg/m2 on days 1 and 8 of a 21 day treatment cycle [29]. The most common doselimiting toxicities are neutropenia, and myelosuppression, and the Gem dose can be
reduced by 75% to combat these side effects [29]. Patients treated with single agent
Gem experienced an average of 6 months of additional life [28, 30].
The introduction of FOLFIRINOX in 2010 provided PDAC patients with the first
viable alternative to Gem that could offer improved results. FOLFIRINOX is a
combination of 3 chemotherapeutic agents plus a derivative of vitamin B. The name
FOLFIRINOX itself is an acronym which represents: folinic acid (FOL) – a vitamin B
derivative included to combat the side effects of fluorouracil, fluorouracil (F) – a DNA
damaging agent and antimetabolite which halts DNA synthesis, irinotecan (IRIN) – a
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topoisomerase inhibitor, and oxaliplatin (OX) – a platinum-based antineoplastic,
regarded as a DNA damaging agent, which eventually leads to inhibition of DNA
synthesis and repair [31].
Patients treated with FOLFIRINOX enjoy a significant improvement in survival,
with an average of 11.1 months compared with 6.8 months for Gem [32]. Unfortunately,
FOLFIRINOX is also associated with increased adverse events, including grade 4
neutropenia, febrile neutropenia, thrombocytopenia, diarrhea and sensory neuropathy.
Because of its increased toxicity, FOLFIRINOX is only recommended to patients
exhibiting a good performance status [32].
Fortunately for PDAC patients for whom FOLFIRINOX is not a viable option, a
combination of Gem and Abraxane (Gem-Abraxane) is now available. Treatment with
Gem-Abraxane improved median survival time to 8.5 months over 6.7 months for Gem
alone, and improved the one-year survival rate of patients by 13% (35% vs. 22%) [33].
Additionally, Gem-Abraxane demonstrated a survival benefit and increased quality of life
in patients exhibiting a poor performance status [34]. Unfortunately, Gem-Abraxane
treatment still exhibits significant toxicity, including grade 3/4 neutropenia, leukopenia,
neuropathy, febrile neutropenia, and fatigue [34].
Abraxane is comprised of Paclitaxel (a taxane) bound to albumin. The taxane
class of drugs targets and kills dividing cells. The method of action involves binding to
tubulin, which effectively abrogates mitosis and intracellular protein transport [35].
Albumin protein is bound to Paclitaxel to increase solubility and absorption [2]. GemAbraxane’s efficacy was originally thought to be based on a synergistic effect between
the two drugs, brought about by their ability to target mitotic cell division via different
mechanisms. Surprisingly, however, the observed synergy appears to result from
Abraxane’s ability to increase intra-tumoral Gem concentration through a mechanism
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that is not fully understood [36]. Combination therapy, drug resistance, and toxicity will
be further discussed in subsequent chapters of this work.

Conclusion
The human pancreas is a complex organ which serves an endocrine and
exocrine function. The endocrine pancreas acts as a regulator of blood glucose
concentration, while the exocrine pancreas secretes zymogens which eventually
become the enzymes responsible for lipid, protein, and carbohydrate digestion.
Although relatively rare, tumors of the pancreas are devastating, and their
incidence is increasing. Surgical resection before metastasis is the only curative
treatment. Due to a lack of screening tools and an absence of early symptoms, most
patients present with late-stage unresectable disease. Effective chemotherapies remain
the best hope for the majority of pancreatic cancer patients.
Over 90% of pancreatic cancers arise in the ducts of the exocrine pancreas [37].
Ductal tumors are associated with significant scarring and desmoplasia. The acellular
component of PDAC typically constitutes most of the tumor volume and is associated
with PDAC’s chemo-resistant nature. Unfortunately, depletion of the stroma worsens the
disease, revealing the dynamic and complex nature of this tumor.
Combination therapies offer the most effective option for advanced stage
patients; however, these treatments are associated with increased toxicity that many
patients are not able to tolerate. Furthermore, even though combination treatment offers
the best outcome, they still on average only provide less than one year of additional life.
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Effective, less toxic new treatments are desperately needed to combat this devastating
disease.

Drug Resistance, Combination Therapy and HDACi

Introduction
Drug resistance is a hallmark of PDAC. One major strategy to combat drug
resistance has been combination chemotherapy. The success of both FOLFIRINOX and
Gem-Abraxane is testament to the benefit of this strategy. Unfortunately, although
combination regimens have provided improved results in PDAC patients, drug
combinations are almost uniformly associated with increased toxicity over single-agent
treatment. Multiple clinical trials have been abandoned, not because of lack of efficacy,
but because of dose limiting toxicities.
The realization that epigenetic dysregulation could be a driver of PDAC sparked
intense research into drugs targeting different regulators of the epigenome.
Accumulating evidence indicates that drugs targeting epigenetic changes, specifically
HDAC inhibitors (HDACi), can prevent or reverse drug resistance. Thus, this new area
of study opens the possibility of a low dose combination regimen that may avoid many of
the toxicities of other combination therapies.

Drug Resistance
Inherent and acquired drug resistance is arguably the greatest obstacle clinicians
face in treating PDAC. Drug resistance is credited as being the most common reason
for discontinuation of treatment [38].
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Desmoplasia and the restrictive tumor microenvironment act to prevent
chemotherapeutic agents from accessing the PDAC cells and are a major factor in
inherent drug resistance. Unfortunately, as mentioned above, depletion of the tumor
microenvironment leads to increased metastasis and a worse prognosis. Inherent drug
resistance is also attributed to the heterogeneity of PDAC. Studies have demonstrated
that even the smallest clinically detectable tumor, at about 109 tumor cells, will still
contain approximately 1,000 drug resistant cells [39]. These 1,000 cells are enough to
re-populate the tumor after the drug-sensitive cells have been destroyed.
In addition to the inherent drug resistance of PDAC cells, acquired drug
resistance is also in play. Reduced drug uptake and increased drug efflux after
exposure to chemotherapy are prevalent in PDAC [40, 41]. Chemotherapy often results
in an increased expression of efflux proteins, including members of the multidrug
resistance protein family (ATP-binding cassette, subfamily C (ABCC) multidrug
transporters) [39, 41]. In relation to Gem, a pyrimidine nucleoside analog, drug uptake is
inhibited by mutations, deletions, or down-regulation of nucleoside transporters, or the
upregulation of nucleoside phosphatases which can lead to the inactivation and
degradation of gemcitabine [40, 42]. Unfortunately, research has demonstrated that
PDAC tumors begin adapting to chemotherapies such as Gem within two weeks of initial
treatment [43]. Although not all tumors are able to adapt quickly enough to avoid
destruction, the cells that are able to acquire a resistant phenotype will quickly repopulate the tumor.

Combination Therapy and HDACi
Clinicians and researchers have attempted to overcome the drug resistance
conundrum in PDAC with combinatorial approaches. Two major combination strategies
have emerged. Initial approaches involved using different drugs to target a single
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process or pathway. Subsequently, as more diverse and precise therapies became
available, researchers began to target different pathways simultaneously.
The combination of the antimetabolite Gem and the mitotic spindle disruptor
Abraxane is an example of targeting two individual aspects (i.e., DNA replication and
mitosis, respectively) of the same process: cell division. The drug combination
FOLFIRINOX is another example, with three separate chemotherapeutic drugs acting to
induce DNA damage and inhibit DNA replication. Unfortunately, as previously covered
in this work, significantly increased toxicity plagues this combination strategy.
Examples of combination therapies targeting two or more disparate processes,
all of which are critical to a cancer cell’s survival/proliferation, include EGFR inhibitors
with Gem [44, 45] and the HER2 pathway inhibitor, lapatinib, with Gem [46]. In contrast
to single process targeting, combination therapies that target more than one pathway are
not plagued by toxicity but are limited by lack of efficacy. Unfortunately, the survival
benefit of these combination trials has been measured only in weeks. Thus, a third
strategy is now being explored: epigenetic disruption in combination with chemotherapy.

Histone Deacetylase Inhibitors
HDACi are a relatively well described class of drugs that have been utilized in a
wide range of diseases including: mood disorders and depression, cardiovascular
diseases, parasitic infection, inflammatory disease, and cancer [47]
The potential for cancer treatment is a relatively new development in the HDACi
story. HDACi are attractive for cancer therapy because they have demonstrated
selective toxicity to cancer cells over normal cells in vitro and in vivo [48, 49]. The
selectivity of HDACi for tumor cells over non-transformed cells appears to stem from a
defective G2 cell cycle checkpoint, which is re-activated with HDACi treatment [50].
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Accumulating evidence further indicates that HDACi may also target non-proliferating
tumor cells by promoting apoptosis [51]. Perhaps most significantly, HDACi have
demonstrated significant synergy with Gem [52, 53] and this synergy could, in part, be
attributed to the reversal of acquired drug resistance [52, 54-56]. This discovery has led
researchers to study the interaction between HDACi and Gem in PDAC, with the hope of
designing an ideal drug combination.
HDACi can be divided into two broad classes: pan-HDACi and specific HDACi.
While the pan-HDACi target multiple classes of the HDAC family, the specific-HDACi
target specific classes of HDACs or even individual HDAC proteins. An in-depth
description of the different HDAC proteins is provided in Section 3 of this work. As a
general rule, HDACi occupy the zinc binding pocket of the HDAC catalytic site [57] and
are categorized by the structure of their zinc binding group. The seven major classes of
HDACi are: hydroxamic acids, benzamides, carboxamides, cyclic peptides,
hydroxyacrylamides, isothiocyanates, and short chain fatty acids [58].
The prototypical HDACi, butyric acid (a short chain fatty acid) was discovered as
a natural product of bacterial fermentation of dietary fiber in the large bowel [59]. The
anti-neoplastic effects of butyric acid were observed soon after its ability to modify
histones was described. However, it was not until much later that its mechanism of
action was elucidated.
In 1977 and 1978, butyric acid was reported to be a potent effector of histone
modification [60, 61] and an inhibitor of histone deacetylation [62, 63]. Shortly
afterwards, it was discovered to significantly increase apoptosis in cancer cells in culture
[64]. Given its ability to function as a nuclear disrupter and anti-neoplastic agent, butyric
acid has been utilized in the laboratory for decades; however, it was not viewed as a
naturally occurring anti-cancer agent [65] until the discovery that animals fed diets rich in
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fiber produced significant amounts of butyric acid in the colon [66]. The link between
high-fiber diets and reduced rates of colon cancer could be explained by increased
exposure of pre-neoplastic and neoplastic cells to butyric acid [67].
Although the ability of butyric acid to inhibit histone acetylation was known in the
late 1970s, its mechanism of action as an HDACi was not realized until much later. It
wasn’t until 1996 that Tauton, Hassig, and Schreiber isolated and cloned the first HDAC
protein (HDAC1) in humans [68]. In 1999 Finnin and colleagues reported that the panHDACi, Trichostatin A and Vorinostat, both worked to increase histone acetylation by
inhibiting the catalytic site of the classical HDACs [69]. Soon after, in 2003, Davie et al.
described butyric acid as an HDACi [70]. The notion that a naturally occurring HDACi
could prevent and treat cancer led to an explosion of research into HDACi.
Interestingly, in addition to butyric acid, the four clinically available HDACi that
are FDA approved for cancer treatment (Belinostat, Panobinostat, Romidepsin, and
Verinostat) are all derivatives of molecules originally discovered in microorganisms [71].
The secretion of HDACi by bacteria is thought to be a defense mechanism against
eukaryotic organisms [72]. Strong supporting evidence for this notion comes from the
use of Trichostatin A, a hydroxamic acid produced by S. hygroscopius, as a potent
antifungal antibiotic [73]. Additionally, HDACi are secreted or produced by a broad
range of organisms, including archaebacteria, eubacteria, fungi, and plants [71], adding
to the sophisticated evolutionary interaction between HDACi producers and their target
organisms.
The idea that HDACi are a natural product that eukaryotes have evolved with
may help to explain why HDACi show selectivity for cancer cells over non-transformed
cells. Complex conserved evolutionary pathways are beginning to be elucidated that
demonstrate the ability of eukaryotes to overcome HDACi effects [74]. The most
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intriguing evidence of the intrinsic ability of eukaryotic cells to overcome HDAC inhibition
comes from studies on human lymphoblastoid cells exposed to the HDAC inhibitor
Vorinostat for 30, 60, and 120 minutes. The study’s authors discovered that exposure to
Vorinostat resulted in rapid downregulation of genes encoding components of six
enzyme complexes responsible for lysine acetylation (the KAT complexes) [75]. Early
evidence from this work is pointing to disruption of HDAC inhibitor compensatory
pathways as hypersensitivity of some cancers or cancer cell lines to HDACi.

Pan-HDACi in PDAC Treatment
Apart from Romidepsin, all HDACi FDA approved for cancer treatment are panHDACi. The four HDACi that are FDA approved for cancer treatment are used for the
treatment of hematological malignancies [76]. At therapeutic doses for hematologic
malignancies, HDACi have been associated with a wide range of adverse effects
including nausea, vomiting, fatigue, rash, cough, fever, headache, and anorexia.
However, these side effects are typically not severe enough to warrant discontinuation of
treatment [76]. Unfortunately, at the higher doses required to treat “solid tumors,” dose
limiting toxicities are observed.
Of the three FDA approved pan-HDACi, Panobinostat (hydroxamic acid) is more
potent then Belinostat or Vorinostat. Panobinostat demonstrates a significantly longer
elimination time, prolonged hyperacetylation of histone protein and more prominent
modulation of gene expression [77]. The increased potency and elimination time of
Panobinostat allows clinicians to utilize intermittent dosing schedules with the intention
of reducing off-target effects [77]. The advantages of Panobinostat over Belinostat and
Vorinostat have made Panobinostat the drug of choice for mono- and combination
therapies in PDAC.
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Three major side effects are associated with pan-HDACi: myelosuppression,
cardiac toxicity, and severe diarrhea [76]. Unfortunately, clinical trials utilizing
Panobinostat have had to be terminated early because of severe treatment-related
toxicity including neutropenia, thrombocytopenia, tachycardia, and grade 3/4 diarrhea
[78]. Although the clinical trials utilizing single agent Panobinostat were terminated
prematurely due to dose limiting toxicities, positive treatment responses such as delays
in tumor growth, reduced metastasis, and a reduction in tumor burden were observed
[78]. These mixed results suggested that HDACi may provide a viable therapeutic
option in PDAC, but only if the toxicity can be managed.

Panobinostat in Combination with Gemcitabine in PDAC
Research using PDAC cell culture models demonstrated that pan-HDACi
synergize with Gem [52, 53]. Surprisingly, the studies also demonstrated pan-HDACi
treatment yeilded increased efficacy after tumor cells acquire Gem resistance [55]. Early
evidence suggested the significant synergy observed between HDACi and Gem is due
to the ability of HDACi to up-regulate the cyclin-dependent kinase inhibitor p21
independently of p53 [79].
Gem treatment of PDAC tumor cells is associated with arrest in the G1 phase of
the cell cycle [80]. In contrast, increased expression of p21, a hallmark of pan-HDACi
treatment [81], is associated with arrest in both the G1 and G2/M checkpoints [82, 83].
Panobinostat’s ability to arrest the cell cycle in both the G1 and G2/M checkpoints (see
Figure 7 below) may overcome the ability of PDAC cells to escape G1 arrest.
Panobinostat also drives PDAC cells to undergo apoptosis via up-regulation of the proapoptotic proteins, Bax, Bak, and Bim, and down-regulation of anti-apoptotic XIAP, Mcl1, and Bcl-2 proteins [78, 84, 85]. The ability of Panobinostat to induce apoptosis is
most likely a significant factor in its synergy with Gem, given that Gem only targets
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dividing cells. HDACi treatment also alters the expression of membrane transport
proteins associated with Gem resistance [55, 86, 87] and this may be a major contributor
to the ability of HDACi to reverse acquired drug resistance in Gem-treated cells.
The laboratory work on pan-HDACi in PDAC has translated to partially
successful clinical trials, with patients experiencing significant survival benefits over
chemotherapy or HDACi alone [79]. Unfortunately, clinical trials of pan-HDACi in
combination with Gem have elicited similar dose limiting toxicities to single agent HDACi
monotherapies, including myelosuppression and grade 4 diarrhea [88]. Given the
clinical evidence, pan-HDACi combination therapy does not arrear to be a viable option
for PDAC treatment.

Selective HDACi in PDAC Treatment
A battery of selective HDACi have been developed and these agents are being
used both in research as well as in clinical settings. As a more comprehensive
understanding of the HDAC proteins is realized (covered in next chapter), it has become
apparent that pan-HDACi should be utilized as proof-of-principle tools and not in clinical
treatment. Pan-HDACi toxicities are almost certainly related to their broad spectrum
HDAC inhibition. The generally low toxicity of selective-HDACi indicates that inhibition of
specific HDAC proteins can be accomplished without adverse effects.
The toxicity of the selective-HDACi depends upon the HDACs targeted. HDAC6
for example, can be deleted in mice with very minimal impact [89]. Not surprisingly,
HDAC6 inhibitors are non-toxic [90, 91]; however, not all specific-HDACi are non-toxic.
The FDA approved drug Romidepsin, a selective inhibitor of HDAC1 and HDAC2 elicits
significant adverse effects, including sudden death, when used at therapeutic doses for
solid tumors [76].
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The Histone Deacetylase Proteins

Introduction
The histone deacetylase (HDAC) proteins are a group of enzymes best known
for their ability to remove acetyl groups from the N-terminal tails of histone proteins,
resulting in epigenetic regulation of gene transcription. Deacetylation of histones, for
which the HDACs are named, is likely not their primary function. The HDAC proteins
have been grouped into four classes (I-IV), all of which have been identified in all fully
sequenced free-living eukaryotic organisms (excluding fungi). Class I, II, and IV HDACs
also exist in eubacteria and class II HDACs have been identified in archaebacteria.
Phylogenetic analysis suggests that class II HDAC proteins existed in the common
ancestor of all extant forms of life [92]. Although organisms as ancient as the Archaea
bacteria utilize histone like proteins to package their DNA into layered hypernucleosome
type structures, these histones lack the N-terminal tail region and have not been
demonstrated to be acetylated [93]. Given their ubiquitous expression among
prokaryotes including the Archaea, HDAC proteins almost certainly predated histone
proteins.
Acetylation/deacetylation of non-histone proteins is critical for protein activation,
deactivation, phosphorylation, methylation, ubiquitination, sumoylation, as well as protein
folding and turnover [94, 95]. The ability of HDACs to deacetylate non-histone proteins
is well documented; however, the realization that non-histone protein deacetylation could
be a primary function of the HDACs is relatively new. Understanding of the significant
role of HDACs in non-histone protein regulation led to an increased appreciation for the
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intracellular location, proteins/processes involved in HDAC shuttling, and the
structural/functional and tissue diversity of HDAC proteins. The recent recognition of the
role of HDACs as global protein regulators has revolutionized how researchers have
approached HDAC regulatory functions in gene expression as well as the potential of
HDAC inhibitors for the treatment of human disease, including cancer.

Acetylation Status and Gene Transcription
A major factor in gene transcription is access. For transcription to occur, the
transcription machinery, as well as ancillary proteins, need access to target genes.
Multiple epigenetic mechanisms exist to regulate protein expression via transcriptional
control; one of the best studied and characterized is modification of the N-terminal tails
of histone proteins.
In eukaryotic organisms, a stretch of 147 base pairs of DNA is wrapped around a
histone octamer, comprised of an H3-H4 tetramer and two H2A-H2B dimers. This
protein/DNA complex is referred to as the “nucleosome”. Nucleosomes are then linked
together by a third histone protein (H1), forming a 30nm solenoid structure commonly
referred to as chromatin [96]. Chromatin can be further divided into the “open” or
transcriptionally active euchromatin, and the “closed” or transcriptionally inactive
heterochromatin.
Heterochromatin is DNA in its most protected and compact state. For the DNA to
be assembled into heterochromatin, it must be folded into close proximity with itself. The
histone proteins in the nucleosome are bound to the DNA via an electrostatic attraction
between the negatively charged phosphate backbone of the DNA and the positively
charged amino acid residues in the core globular histones. For full DNA compaction into
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heterochromatin, however, the intrinsic negative charge of the DNA must be overcome,
and the nucleosome core particle cannot accomplish this task. Possessing a charge of
+144e, the core histone complex is not able to neutralize the -294e charge of the 147
base pairs of DNA wrapped around it, leaving the nucleosome with a net charge of 150e [97]. For the DNA to fully condense into heterochromatin, the positively charged
lysine residues of the histone tails are required. In contrast, “opening up” or “relaxing”
the heterochromatin into euchromatin is achieved by neutralization of the positively
charged lysines on the N-terminal tails [98].
The N-terminal histone tails act as a major epigenetic regulator of gene
transcription, and can undergo at least 12 different types of post-translational
modifications including: acetylation, methylation, phosphorylation, sumoylation,
ubiquitination, ADP ribosylation, butylation, citrullination, crotonylation, formylation,
proline isomerization and propionylation [99]. In this dissertation, analysis will focus on
acetylation.
Acetylation occurs when histone acetyltransferase (HAT) proteins transfer the
acetyl moiety of acetyl-CoA to the ϵ-amino group of lysine residues. Removal of acetyl
groups from the histone tails is accomplished by HDACs. This is a highly conserved and
ubiquitous process, described in every eukaryote examined [100]. The acetylation state
of histone tails has been directly and indirectly correlated to gene transcription by
dictating higher order chromatin structure and recruitment of transcriptional enzyme
complexes to specific regions of the genome [101]. Histone acetylation is also extremely
transient, with the average half-life of an acetyl-lysine being 60-120 minutes [102]. This
makes acetylation among the most temporary regulators of gene transcription. The
acetylation state of chromatin is in perpetual flux, dictated by the number of HAT and
HDAC proteins as well as their co-repressor, co-activator and targeting proteins [103].
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Recent advances in the understanding of epigenetics, combined with targeted
pharmacologic inhibitors, have made the HDAC proteins an exciting target for disease
research.

The 18 Human HDACs
The HDAC proteins can be divided into two major groups: the classical or metaldependent HDACs and the sirtuins. The division is based upon the enzymatic co-factor
utilized in the deacetylation reaction. The sirtuins, or class III HDACs, utilize NAD+ as a
reactant for deacetylation. The classical HDACs (class I, II, and IV) utilize zinc as a cofactor. The research described in this dissertation focuses solely on the classical
HDACs (Figure 1).
The classical HDAC enzymes share a highly conserved 390 amino acid catalytic
domain, which utilizes an ion of zinc to bring the carbonyl carbon of the acetyl group into
proximity with a molecule of water for nucleophilic attack. Upon termination of the
deacetylase reaction, the acetyl group is dissociated as carboxylic acid and the lysine
residue is returned to its positively charged state [69].
In humans, the HDAC family consists of 18 proteins: 11 classical HDACs and 7
sirtuins. The 11 classical HDACs are further subdivided into three major classes: I, II,
and IV. Individual classes are further categorized into sub-classes designated a and b.
The HDAC classes were named after their similarity to yeast proteins. Class I HDACs
most closely resemble the yeast Rpd3 protein and the class II HDACs resemble yeast
Hda1. The class IV HDACs demonstrate a mixture of both class I and class II
characteristics [92].
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Figure created from referenced works[103-108]
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The conservation of HDAC classes across divergent organisms points to nonredundant roles of these groups of enzymes [92]. However, significant overlap in
function and structure is observed within each class, and HDACs do not usually perform
their enzymatic function independently. As a rule, HDAC proteins are extremely
interdependent and are typically members of large multi-protein complexes which
include other HDACs as well as regulatory and scaffolding proteins. A brief review of
each individual HDAC as it relates to its class and sub-class is provided.

Classes, Subclasses, and Individual HDACs
Class I – The class I HDACs include HDACs 1, 2, 3 and 8 and have been
demonstrated to account for over 50% of the histone deacetylase activity in embryonic
stem cells [109]. Class I HDACs are, in general, ubiquitous in expression [110] and
primarily located in the nucleus. A major hallmark of this class is participation in large
stable multiprotein complexes, although recent work has demonstrated that HDAC1 (and
possibly all the class I HDACs) is able to directly bind chromatin [111]. These
complexes are typically recruited to DNA via transcription factors and DNA binding
proteins [98]. The cell utilizes these protein complexes to target class I HDAC activity to
specific regions of the genome and the dependence on large protein complexes allows
for strict regulation. It is not surprising that the deacetylase activity of the class I HDACs
is greatly reduced when they are in isolation [112].
The class I HDACs are further subdivided into class Ia (HDAC1 and 2) and class
Ib (HDAC3 and 8). As previously stated, significant overlap is observed within HDAC
subclasses. HDACs 1 and 2 share 82% amino acid identity [113] and will typically
associate to form heterodimers. HDACs 1 and 2 are best characterized in four major
complexes: NuRD, Sin3, CoREST and MiDAC [114]. The protein complexes serve very
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diverse functions, which are still being described. For example, the NuRD complex is
recruited by the polycomb and hunchback repressors and is involved in silencing large
clusters of genes. In contrast, Sin3 is recruited via nuclear hormone receptors and is
associated with silencing specific genes [115].
Although HDACs 1 and 2 are very similar both in structure and function, they
undoubtedly serve some disparate functions. Studies have demonstrated that
homozygous deletion of HDAC1 in mice is embryonically lethal [116, 117], whereas mice
with homozygous deletion of HDAC2 survive until the perinatal period, eventually
succumbing to multiple cardiac defects [117]. Like the class Ia HDACs, class Ib HDACs
(HDACs 3 and 8) participate in multi-protein, multi-HDAC targeted complexes. However,
members of class Ib differ from those of class Ia in that HDAC3 and 8 do not share
significant sequence homology [92] and are typically not found together.
HDAC8 differs significantly from its class I cohorts. Phylogenetic analysis has
indicated that HDAC8 is restricted to vertebrates [92]. Unlike its peers, HDAC8 is tissuespecific and is expressed almost exclusively in the cytosol of smooth muscle [94]. Most
interestingly, HDAC8 appears to have evolved a preference for potassium or sodium
over zinc as its monovalent cation co-factor [118].
Unlike HDAC8, HDAC3 is considered the only vertebrate member of an ancient
invertebrate subclass and is widely expressed in tissues [92]. Although it is ubiquitously
expressed, HDAC3’s activity is actually regulated by additional tissue specific HDACs.
Interestingly HDAC3 appears to provide the deacetylase action for the entire HDAC
class IIa subgroup. An extensive characterization of the HDAC3/class IIa interaction will
be covered later in this work. In addition to the class IIa HDACs, HDAC3 relies upon
binding to two major co-repressor complexes for enzymatic activity: SMRT (silencing
mediator for retinoid and thyroid receptors) and N-CoR (nuclear receptor corepressor)
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[107] (Fig. 1). The SMRT/N-CoR co-respressors contain a deacetylase activation
domain (DAD) which is exclusively required for HDAC3 enzymatic activity [119, 120].
The SMRT/N-CoR/HDAC3 complex also dictates HDAC3’s intracellular location. Unlike
its other class I cohorts, HDAC3 contains both an NLS (nuclear localization signal) and
an NES (nuclear export signal) (Figure 1). The SMRT/N-CoR complex, in conjunction
with the class IIa HDACs, is responsible for shuttling and targeting HDAC3 to its desired
intracellular location [105, 121].
HDAC3 has been extensively characterized as being essential for DNA double
strand break repair. Inactivation of HDAC3 in mouse embryo fibroblasts (MEFs) resulted
in defects in non-homologous end joining after ionizing radiation exposure [122].
Additionally, when siRNA is utilized to knock down HDAC3 in mitotically active HEK 293
cells, the homologous recombination pathway utilized to repair double strand DNA
breaks is inhibited [123].
Class II – The class II HDACs include HDAC4, 5, 6, 7 ,9 and 10 and are
significantly more tissue-specific than class I enzymes [124]. With the exception of
HDAC6, which is almost entirely cytoplasmic [125], the class II HDACs shuttle between
the nucleus and the cytoplasm [94].
Class IIa enzymes (HDAC4, 5, 7 and 9) contain distinct N-terminal and Cterminal domains and, surprisingly, are catalytically inactive due to a tyrosine-to-histidine
mutation in the deacetylase domain [126, 127]. Instead of direct deacetylase activity,
the class IIa HDACs function as activating, coordinating and targeting proteins for
HDAC3 [126]. The catalytically inactive HDAC domain of the class IIa HDACs binds to
the RD3 region of SMRT/N-CoR (Fig 1) [128]. Upon binding to the SMRT/NCoR/HDAC3 complex, class IIa HDACs utilize an approximately 600 amino-acid N-
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terminal extension as platform for additional protein-to-protein interactions and post
translational modifications [129].
Each of the four different class IIa HDACs contains a novel N-terminal regulatory
domain, with an overall sequence homology between individual class IIa HDACs of only
30-45% [106]. The diversity of the N-terminal regulatory domains allows for a wide array
of regulatory proteins to indirectly interact with and target HDAC3, with the best
characterized being the MEF2 (myocyte enhancer factor) DNA anchoring transcription
factors [106].
In addition to the N-terminal regulatory domain, the class IIa HDACs contain a
binding site for 14-3-3 nuclear export protein, which can be activated by phosphorylation
via multiple kinases such as protein kinase D and salt inducible kinase (SIK) [130].
Interaction with 14-3-3 protein results in cytoplasmic retention of the complex and
prevention of histone modification and subsequent transcriptional suppression of genes
targeted by the class Ila complex [131]. Dephosphorylation via phosphatases such as
PP1, PP2 and myosin phosphatase allows for 14-3-3 disassociation and nuclear import
of the HDAC3/SMRT/N-CoR/HDAC class IIa complex, and subsequent target gene
repression [132].
The class IIb enzymes (HDAC6 and 10) are significantly different from all the
other classic HDACs. HDAC6 and 10 both contain two deacetylase domains, although
the second domain in HDAC10 is vestigial. Given that HDAC6 and 10 do not selfassociate and are catalytically active as monomers, it has been hypothesized that the
duplication of the catalytic domain may satisfy the requirement for dimerization or
association [92].
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HDAC6 is primarily cytosolic [133] while HDAC10 is primarily nuclear [134].
HDAC6 contains an additional C-terminal zinc finger domain which can interact with
mono and polyubiquitin and ubiquinated proteins [133]. HDAC6 has been determined to
be instrumental in the formation of the aggresome in the misfolded protein response as
well as being critical to the induction of the heat shock proteins [134, 135]. A major
target of HDAC6 is alpha-tubulin. Surprisingly only one of HDAC6’s two catalytic
domains possesses alpha-tubulin deacetylase activity and inhibitors must be targeted to
this domain for alpha-tubulin hyperacetylation to occur [136]. HDAC6 null mice
demonstrate global hyperacetylated alpha-tubulin [89]. This was an interesting finding
because the level of HDAC6 in tissues did not correlate with the level of alpha-tubulin
acetylation. This may reflect the ability of HDAC6 to associate with the class III HDAC,
SirT2, to deacetylate alpha-tubulin [137] and the possibility that total loss of HDAC6 may
abrogate SirT2 deacetylase ability.
Class IV – The class IV group includes only one member: HDAC11. HDAC11 is
the smallest of the classical HDACs, with 4/5 of the protein being dedicated to its
catalytic domain [100]. It has been designated in its own class because it shares
sequence similarities with both the class I and class II HDACs [92]. HDAC11 can be
nuclear or cytoplasmic and is mainly expressed in the heart, brain, skeletal muscle and
testis [100]. HDAC11 does not participate in any of the classic HDAC class I or II
complexes but does interact with HDAC6 [138].
HDAC11 expression is especially high in neutrophils compared to other myeloid
cells and HDAC11 deficiency leads to a more aggressive neutrophil population [139].
Recent research indicates that HDAC11 is an immune attenuator, with deficiency or
inhibition of HDAC11 leading to suppression of IL-10 and development of more rapid
and potent graft-versus-host disease [140].

38

Conclusions
The HDAC proteins are an ancient and highly conserved family of proteins that
almost certainly predate their role as histone acetytransferases and transcriptional
repressors [93]. The 18 HDAC proteins coded in the human genome are non-redundant
and perform a highly diverse array of functions throughout the cell. Individual HDAC
expression can be ubiquitous or tissue specific. The intracellular location of HDAC
protein can be nuclear, cytoplasmic, or both, dependent upon the specific HDAC protein.
HDACs deacetylate both histone and non-histone proteins and act as master epigenetic
regulators of gene transcription. Histone deacetylation results in “closed” chromatin and
repression of transcription. However, HDAC inhibition often leads to increases in the
expression of certain genes. These phenomena can be attributed to the targeting of
HDACs to specific regions of the genome via repressor complexes.

Objective of the Work
A successful clinical trial must begin with a solid foundation in pre-clinical study.
As previously covered in this work, strong evidence from several studies supports the
combination of HDACi with Gem as an effective treatment modality in PDAC.
Unfortunately, because of treatment-related toxicity HDACi have not taken a place in the
PDAC treatment arsenal. Selective HDACi, when utilized correctly, can target the HDAC
proteins that are dysregulated in cancer as well as HDACs that are relied on by cancer
cells. As previously referenced in this work, cancer cells can lose their ability to manage
HDAC inhibition, producing a significant tolerance disparity between healthy and
transformed cells.
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In the same way that the thousands of genetic alterations in PDAC can be
distilled down to four critical protein mutations/deletions, the dysregulation in HDAC
expression can be narrowed to 2 classes of HDACs. Research has identified HDAC
classes I and II as being disproportionately dysregulated in PDAC [141, 142]. Beginning
with 6 members of the class I and II HDACs, a tailor-made HDACi cocktail can be
developed based on the vulnerabilities of PDAC.
Our study was conducted in two phases. Phase I aimed to elucidate the HDAC
protein(s) required by PDAC cells for survival and proliferation. Next, selective targeting
of required HDACs in combination with Gem was performed to determine if the identified
proteins were also responsible for pan-HDACi synergy with Gem. The final goal of our
work was to build a custom drug regimen to target the specific HDACs critical for PDAC
maintenance and whose targeting was essential for synergy with Gem. Phase II of our
study was focused on determining if our novel HDACi/Gem combination would be
tolerated in an animal model.

Experimental Design
Human PDAC cell culture models were utilized to study tumor response to HDAC
loss through siRNA knockdown (KD) and pharmacological inhibition. PDAC cell lines
were also utilized for synergy and apoptosis studies with drug combinations. After a
successful drug combination was discovered, athymic nude mice were employed to
establish toxicity and efficacy in an animal model.
Human PDAC cell lines were selected to represent different combinations of the
four most common genetic mutations in PDAC (KRAS, CDKN2A, p53, and SMAD4)
[143]. Western blotting was performed on all cell lines selected to establish endogenous
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expression of the class I and II HDACs studied (Figure 5).
Critical class I and II targets were determined by a combination of siRNA KD and
class I and II targeted inhibitors. MTT assay was performed on HDAC KD cells in the
absence and presence of drugs. Differences in cellular proliferation as measured by
MTT assay were utilized to narrow down critical HDAC drug targets, and increasingly
specific HDACi were tested. Drugs were administered for 72 h to allow for three cell
divisions under Gem exposure, and cells were always exposed to drug at the beginning
of their logarithmic growth phase (Materials and Methods). These two precautions
allowed us to evaluate Gem at its peak performance, yielding a more accurate
evaluation of synergy between Gem and HDACi.
Knockdown (KD) experiments were performed on the human PDAC cell lines
MiaPaCa2 and Capan1 given their amenability to siRNA uptake and targeted protein
KD. Knockdown of each individual class I and II HDAC was determined to be ideal at 48
h (Figure 11). HDAC KD cells were plated in 96-well plates 24 h after siRNA exposure
and drug treatment was initiated the following day (48 h after siRNA exposure) to allow
for maximum combination effect. As shown in Figure 11, very little to no targeting
overlap between different HDAC proteins was observed with our KD method (Materials
and Methods).
As previously mentioned in this work, published data demonstrate that panHDACi can induce cell cycle arrest in both G1 and G2/M phases. Gem, however, has
been determined to halt the cycle only in G1 phase. Cell cycle analysis was performed
to determine if the G1 and G2/M cell cycle arrest could be reproduced with the panHDACi, panobinostat, and to determine if panobinostat effects could be recapitulated
with targeted HDACi.
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In PDAC, HDACi are believed to induce significant increases in apoptosis [144,
145]. Apoptosis has been proposed to be a major mechanism in the synergy observed
between Gem and HDACi, via HDACi’s ability to target non-dividing PDAC cells in
addition to the actively dividing cells targeted by Gem. AnnexinV-FITC staining was
therefore utilized to determine the effects of combination treatments over each HDACi
alone and GEM alone on apoptosis. Apoptotic effects were also evaluated by Western
Blot analysis of cleaved PARP and Caspase3.
Finally, successful synergistic drug combinations identified using cell line models
were evaluated for efficacy and toxicity in animal models. Athymic nude mice were
subcutaneously and/or orthotopically implanted with GFP-labeled human PDAC tumor
cells and, after allowing enough time for tumors to establish, subjected to identified
treatment regimens and observed for any toxic effects (Materials and Methods). Mice
were also evaluated for tumor burden and metastasis to determine if drug regimens
provided measurable benefit in vivo.
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Results
The studies performed in this work explored the potential of HDACi as valuable clinical
tools for the treatment of PDAC. Previous clinical studies demonstrated that the panHDACi, Panobinostat, is an effective chemotherapeutic in combination with gemcitabine,
despite significant off-target toxicity [88]. Utilizing CalcuSyn computer software in
conjunction with MTT assays, we recreated the synergy/additivity observed between
Panobinostat and gemcitabine in four human PDAC cell lines: MiaPaCa-2, Capan-1,
CFPAC, and T3M4 (Figure 2i / Table 1/2). These experiments involved combination of
Panobinostat and gemcitabine at equipotent ratios of their respective EC50 values in
PDAC cell culture and analysis via MTT assay (Figure 2i, Table 2). The MTT results
were then analyzed using CalcuSyn computer software to determine Combination Index
(CI) values for the drug combinations. A CI value equal to 1 indicates the drugs are
additive and no synergy has been observed, CI values over 1 indicate antagonism and
values under 1 indicate synergy (Table 1). The closer the CI value is to zero the better
the synergy. The Panobinostat/gemcitabine combination studies demonstrated synergy
in two of the four PDAC cell lines tested, Capan-1 and CFPAC (Figure 2i). T3M4 cells
demonstrated additivity while the MiaPaCa-2 cells showed antagonism with the
Panobinostat/gemcitabine combination. In agreement with previously published
literature, Panobinostat was able to induce apoptosis in the low nanomolar range, as
evidenced by cleavage of PARP and Caspase 7 on Western blot analysis (Figure 3).
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Although Panobinostat has demonstrated significant potential in the clinic,
especially in combination with traditional chemotherapies, off-target toxicities have
prevented it from being utilized for pancreatic cancer therapy. As is further explored in
the Discussion section of this work, the toxicity related to Panobinostat is most likely due
to targeting HDACs which are not necessary for PDAC treatment. Panobinostat is a
highly potent pan-HDACi, which targets all 11 classical HDACs in the low nanomolar
range [146]. As discussed in the Introduction section, HDAC1, 2, 3, 4, 5, and 6 are often
over-expressed in PDAC [141]. Experiments in this work focused on these six HDACs
to identify those that are critical to Panobinostat’s anti-tumor response and synergy with
gemcitabine, and in an effort to reduce/eliminate off-target toxicities of HDAC inhibition.

Effects of Mocetinostat and LMK-235 in PDAC Cell Lines
Initial experiments were performed to determine if inhibition of HDACs 1, 2, 3, 4,
5 and/or 6 is sufficient to recapitulate the synergy/additivity observed with the
gemcitabine/Panobinostat combination. The requirement for HDACs 1, 2, and 3 was
explored using Mocetinostat [147], an inhibitor of HDACs 1, 2, and 3. Experiments to
determine the requirement for HDACs 4, 5, and 6 used the potent inhibitor LMK-235
[144] and Droxinostat was tested to evaluate the effects of combined inhibition of
HDACs 3, 6, and 8 [145] (Table 3). Cells were treated with the maximum biologically
relevant dose (10 µM) of the HDAC inhibitors, and effects of these agents were
compared with those of Panobinostat on the apoptosis markers PARP and Caspase 7
(Figure 3). Experiments in MiaPaCa2 cells revealed that Panobinostat, Mocetinostat,
and LMK-235 similarly increased PARP and Caspase 7 cleavage at 24 h, while
Droxinostat was unable to induce these effects (Figure 3).
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The similarity between the effects of Mocetinostat, LMK-235 and Panobinostat led us to
further explore the more selective drugs in PDAC cell culture models.
Mocetinostat and LMK-235 showed antitumor activity in PDAC cell lines with
ED50 values in the high nanomolar to low micromolar range (Table 4). The specificity of
the drugs for individual HDACs was confirmed by Western blot analysis of protein
acetylation. Consistent with its ability to inhibit HDACs 1, 2, and 3, Mocetinostat
upregulated acH3(K9) (a common histone target indicating HDAC inhibition), but failed
to upregulate the HDAC6 specific activity marker ac-α-tubulin in PDAC cells (Figure 4).
LMK-235 upregulated acH3(K9) and ac-α-tubulin, consistent with its ability to inhibit
HDACs 4, 5, and 6. Follow-up studies confirmed that the HDACs targeted by
Mocetinostat and LMK-235 are expressed in the PDAC cell culture models used in this
study: HDACs 1-6 are expressed at various levels in all five cell culture models
analyzed (MiaPaCa2, Capan-1, BxPC3, Panc1, and CFPAC) (Figure 5).
Given that HDACs 1-6 are the most commonly overexpressed HDACs in PDAC
[141, 142], we hypothesized that Panobinostat’s anti-tumor activity in PDAC may be due
to inhibition of these six enzymes. If our hypothe sis was correct, the combination of
Mocetinostat and LMK-235 should prove synergistic. As shown in Figure 6, the
combination of Mocetinostat and LMK-235 demonstrated significant synergy, with CI
values ranging from approximately 0.5 (synergistic) in BXPC3 cells to 0.8 (weakly
synergistic) in CFPAC cells.
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Having established a similar activity profile for Panobinostat and the
Mocetinostat/LMK-235 combination, cell cycle analysis was performed to further
elucidate the mechanism of action of these agents in PDAC cells. A major mechanism
underlying the activity of HDACi, including Panobinostat, is their ability to halt cell cycle
progression at both the G1/S and the G2/M checkpoints [148]. Studies have
demonstrated that pan-HDACi such as Vorinostat and Belinostat exert their influence on
the cell cycle by inducing the expression of p21 protein [83, 149]. Further evidence has
suggested that the synergy between HDAC inhibition and gemcitabine lies in the ability
of HDACi to upregulate p21 independently of p53 and to subsequently arrest the cell
cycle at the G2/M checkpoint [79].
Western blot analysis confirmed the ability of Panobinostat to upregulate p21
protein in CFPAC cells (Figure 7). Using p53 null HCT116, we further demonstrated
that the effect is p53-independent, a point of contention in the literature [150, 151]. Flow
cytometric analysis of propidium iodide-stained, nocodazole-synchronized CFPAC cells
confirmed Panobinostat’s ability to induce cell cycle arrest at both the G1/S and G2/M
cell cycle checkpoints (Figure 8). In contrast, Mocetinostat showed a significantly
reduced ability to induce arrest at the G1/S checkpoint (Figure 8). LMK-235, however,
demonstrated a similar profile to Panobinostat in its ability to arrest the cell cycle at both
the G1 and G2/M phases (Figure 8). The cell cycle analysis provided evidence that the
two drugs, Mocetinostat and LMK-235, work through different pathways within the cell.
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Consistent with our cell cycle data, the combination of Mocetinostat and LMK235 increased γH2AX expression at 4, 12, and 24 h after exposure (Figure 9). Studies
have demonstrated that γ-H2AX signaling occurs as a result of double strand DNA
breaks, which can coincide with cell cycle arrest [152]. When double strand breaks are
detected, the specialized histone, H2AX, is recruited to the break site and rapidly
phosphorylated at Ser 139 to become γ-H2AX, where it then acts as a scaffold for the
attachment of the DNA repair machinery [153].
To determine if the synergy/additivity observed between Panobinostat and
gemcitabine [83] could be attributed to the class I HDACs inhibited by Mocetinostat or
the class II HDACs targeted by LMK-235, we tested the effects of each drug in
combination with gemcitabine (Figure 10). We observed additivity to antagonism in both
experiments, indicating that the synergy observed between Panobinostat and
gemcitabine most likely reflects combined inhibition of at least one HDAC from two
different classes.
Next, we tested a combination of Mocetinostat and LMK-235 with gemcitabine to
determine if inhibition of HDAC’s 1-6, or a selection of these 6 HDACs, could account for
the synergy observed between Panobinostat and gemcitabine. As demonstrated in
Figure 2i, the Mocetinostat/LMK-235/gemcitabine combination (M/L/G) showed
significant synergy in four PDAC cell lines. The M/L/G combination promoted increased
PARP cleavage over each drug alone, or a combination of Mocetinostat and LMK-235
(Figure 2ii). Given the effects of the Mocetinostat/LMK-235 combination, our next step
was to determine if fewer than the 6 HDACs targeted by Mocetinostat and LMK-235
could deliver the same PDAC toxicity and gemcitabine synergy.
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Increased HDAC Selectivity Recapitulates Antitumor Efficacy in
PDAC Cell Culture Models
To identify the HDACs critical for Mocetinostat/LMK-235 synergy in PDAC cells,
we used siRNA technology to knockdown each individual HDAC targeted by these drugs
(Materials and Methods). As shown in Figure 11, we were able to successfully knock
down all six HDACs in the Capan-1 cell model, with no observable reduction/alteration in
untargeted HDACs. Knockdown was less complete in the MiaPaCa-2 cell line,
especially in the case of HDAC6 (Figure 11). To model inhibition of HDACs 1, 2, and 3
by Mocetinostat or HDACs 4, 5, and 6 by LMK-235, relevant HDACs were silenced in
combination. Successful targeting was demonstrated by the activity markers ac-αtubulin (HDAC6 activity marker) and ac-H3(K9) (general histone acetylation marker)
(Figure 12).
Although individual and combined knockdown of HDACs was largely successful
in MiaPaCa-2 and Capan-1 cells (Figures 11 and 12), MTT assays (72 h) revealed no
significant reduction in cellular viability over non-targeting control treatment as
demonstrated by MTT assay (Figure 13). Possible explanations for the differential
effects of pharmacological inhibition and knockdown of HDACs on cell viability include:
(a) a higher level of inhibition than obtainable with siRNA-mediated knockdown is
needed for the toxicity seen with pharmacological inhibition of these HDACs. This
explanation is supported by data shown in Figure 14, which demonstrate a significantly
more pronounced increase in ac-H3(K9) in the drug-treated cells compared with the
HDAC knockdown cells; (b) the long half-life of HDAC proteins may allow compensation
for the loss of HDAC activity by activation of other genes. For example, HDAC2 has a
half-life greater than 12 h [154], whereas histone acetylation begins to increase in PDAC
cells within 30 m of exposure to pharmacological HDACi [75].
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Cycloheximide studies in our laboratory reinforce the published HDAC half-life
data, with HDACs 1 and 4 not being significantly reduced until 24 h after cycloheximide
exposure (Figure 15). The rapidity with which HDACi exert their effects in PDAC cell
models is demonstrated by our studies in MiaPaCa-2 cells treated with the combination
of LMK-235 and Mocetinostat, with increases in ac-α-tubulin observed after just 1 h of
drug treatment (Figure 15); and (c) Mocetinostat and LMK-235 have off-target effects on
the viability of PDAC cells that are independent of their effects on HDACs.
Follow-up studies employed a strategy in which drug treatment was combined
with HDAC knockdown. Varying concentrations of Mocetinostat or LMK-235 were
administered to PDAC cells silenced for the HDACs targeted by the partner drug. If the
ED50 values for the drug treatment were significantly reduced with HDAC knockdown
over non-targeting siRNA, we could conclude that the synergy observed between
Mocetinostat and LMK-235 was the result of HDAC inhibition and not an off-target effect.
Initial experiments were performed in HDACs 1, 2, and 3 knockdown MiaPaCa-2
cells (Materials and Methods) treated with the HDAC 4, 5, and 6 inhibitor LMK-235. The
ED50 for LMK-235 was modestly affected by HDAC 3 knockdown and significantly
affected by combined knockdown of HDACs 1, 2, and 3 (Figure 16). As demonstrated
in Table 5, the ED50 for LMK-235 was reduced by nearly 70% in the context of HDAC 1,
2, and 3 knockdown. These results pointed to combined class I and II HDAC inhibition
as the basis for Mocetinostat/LMK-235 synergy in PDAC cells.
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Next, we sought to determine if combined inhibition of all three class I HDACs
targeted by Mocetinostat (HDACs 1, 2, and 3) is required for synergy with LMK-235.
Given that HDACs 1 and 2 are paralogs and share 82% sequence homology [113] and
that HDAC 1 is reported to compensate for the loss of HDAC 2 [155]; we hypothesized
that inhibiting only HDACs 1 and 2 may yield similar results to inhibiting HDACs 1, 2, and
3. Our analysis of MiaPaCa-2 and Capan-1 cells revealed that inhibition of HDACs 1
and 2 is sufficient for synergy, with the ED50 for LMK-235 in cells with knockdown of
HDACs 1 and 2 being nearly identical to that in cells with HDACs 1, 2, and 3 knockdown
(Figure 17). As demonstrated in Table 6, knockdown of HDACs 1 and 2 reduced the
ED50 value of LMK-235 by 61% in MiaPaCa-2 cells and by 34% in the Capan-1 cell line.
Consistent with these findings, Western blot analysis of MiaPaCa-2 revealed a similar
increase in cleaved PARP and γH2AX activation with LMK-235 in combination with
HDAC1/2 knockdown or in combination with HDAC1/2/3 knockdown (Figure 18).
Additional experiments explored the effects of Mocetinostat treatment in the
context of HDACs 4, 5 and 6 knockdown. Studies in the Capan1 PDAC cell line
identified HDAC6 as a key target, since the effects of the drug were potentiated to the
same extent by HDAC 4/5/6 knockdown and knockdown of HDAC6 alone (Figure 19,
Table 7). Thus, the synergy between Mocetinostat and LMK-235 appears to further
involve inhibition of HDAC6.
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Taken together, our findings using pharmacological inhibitors and knockdown of
HDACs, individually and in combination, indicated that the synergy observed between
Mocetinostat and LMK-235 is the result of HDAC1, 2, and 6 inhibition. Importantly,
treatment of Capan1 PDAC cells with gemcitabine in the context of HDAC1, 2, and 6
knockdown resulted in a significant reduction in gemcitabine’s ED50, with a decrease in
the effective dose of the chemotherapeutic of 86% (Figure 20 / Table 8). The basis for
Mocetinostat/LMK-235 synergy in MiaPaCa2 cells could not be established, likely
because of incomplete knockdown of HDAC6 in this cell line.

Synergistic effects of HDAC1, 2, and 6 inhibition and
Gemcitabine in PDAC cells
Based on the identification of HDACs 1, 2, and 6 as key targets in the antitumor
activity of HDACi in PDAC, we evaluated the effects of the HDAC-specific drugs,
Romidepsin (ROM) (HDAC1, 2 inhibitor) [156] and ACY-1215 (ACY) (HDAC6 inhibitor)
[157], alone and in combination. As previously reported, ROM is a highly potent inhibitor
of HDAC1 and 2 [156]. ACY is a next generation, highly specific HDAC6 inhibitor with
minimal activity against HDACs 1, 2, 3, 4, 5, 7, and 9, but with slight activity against
HDAC8 [158].
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Romidepsin was determined to be highly toxic to PDAC cell lines, demonstrating
ED50 values in the low nanomolar range in all cell lines tested (Table 9). In agreement
with published work [82, 159], pharmacologic inhibition of HDAC6 by ACY-1215 was not
toxic to MiaPaCa-2 or Capan-1 PDAC cells when administered at concentrations
sufficient to yield full HDAC6 inhibition [159-161]. While MTT assays yielded ED50
values near 5 µM for these cell lines (Figure 21), Western blot analysis pointed to a
maximum HDAC6 inhibitory activity of ACY-1215 at 1 µM, which was the dose we
utilized in our studies (Figure 22). Given the inability of ACY-1215 to produce a
dose/effect relationship at the study dose of 1 µM (Figure 23), ACY-1215 was added at
a fixed dose of 1 μM instead of varying doses at equipotent ratios along with
gemcitabine and Romidepsin.
In initial experiments, MiaPaCa-2 and Capan-1 cells were treated with a
combination of Romidepsin and Gemcitabine (R/G) to establish synergistic activity
(Figure 24). Notably, the effects of the Romidepsin/gemcitabine combination were
significantly enhanced by the addition of 1 µM ACY-1215 (Figure 24). The effects of
these drugs were recapitulated in Panc1, BxPC3, and CFPAC PDAC cells (Table 10),
supporting the generality of the effect.
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The Romidepsin/gemcitabine/ACY-1215 (R/G/A) combination also increased
γH2AX levels, pointing to the induction of double-stranded DNA breaks, as observed
with the Mocetinostat/LMK-235 combination (Figure 14). The triple combination was
also able to elicit an increase in apoptosis as indicated by elevated levels of cleaved
caspase 3 and PARP on Western blots (Figure 25) and by an increase in AnnexV
positive staining cells detected by flow cytometric analysis (Materials and Methods)
(Figure 26).
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Verifying HDACs 1, 2, and 6 as critical for synergy with
gemcitabine in PDAC
To fully establish HDAC1, 2, and 6 inhibition as the basis for the toxicity of
Panobinostat in PDAC cells and the synergy between Panobinostat and Gemcitabine,
we performed additional HDAC knockdown studies and drug substitutions.
HDAC6 knockdown in combination with Romidepsin treatment yielded significant
synergy with gemcitabine in both the MiaPaCa-2 and Capan1 cell lines (Table 11). We
also tested the HDAC6 inhibitor Nexturastat (Figure 22), which was substituted for ACY1215 in combination with Romidepsin and gemcitabine, resulting in strong synergy in
three of the four cell lines evaluated (Table 12i). HDAC 1/2 knockdown shifted the ACY1215 ED50 curve left in Capan-1 and MiaPaCa-2 cells, pointing to a synergistic
interaction (Figure 21). Impressive synergy was also observed when Mocetinostat
(HDAC 1/2/3 inhibitor) was substituted for Romidepsin (HDAC 1/2 inhibitor) in ACY1215/gemcitabine combinations (Table 12ii). Finally, the HDAC6 specific inhibitor WT161, which at higher concentrations will also target HDACs 1 and 2 [162], was utilized as
proof-of-principle that a single drug targeting HDACs 1, 2, and 6 will synergize with
gemcitabine. Significant synergy was observed in four of the 5 PDAC cell lines tested
(Table 13). The lack of synergy in Capan-1 cells could be the result of an intrinsic
toxicity of WT-161 in this cell line. Consistent with this explanation, while Capan-1 cells
displayed the lowest ED50 value for WT-161, Panc1 cells which demonstrated the
greatest synergy also had the highest ED50 value for the drug. It is possible that Capan1 cells were being killed by WT-161 at doses too low to sufficiently inhibit HDACs 1/2
and trigger a synergistic interaction with gemcitabine.
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Combined HDAC1, 2, and 6 inhibition and gemcitabine for the
treatment of PDAC in vivo
After establishing that inhibition of HDACs 1, 2, and 6 is responsible for
Panobinstat’s toxic and synergistic effects in PDAC cell lines in vitro, toxicity trials in
mice were required to determine the safety of the Romidepsin/Gemcitabine/ACY-1215
combination. Based on reported doses in mice of 2 mg/kg twice weekly for Romidepsin,
30-50 mg/kg five days per week for ACY-1215, and twice weekly gemcitabine at 100125 mg/kg (e.g. [163-167]), we demonstrated that 2 mg/kg Romidepsin and 40 mg/kg
ACY-1215 plus 125 mg/kg gemcitabine are non-toxic, as reflected in similar weight gain
to vehicle-treated mice over a three-week period (22% ± 1.4% vs. 21% ± 1.1%) (Figure
27).
We next conducted efficacy studies in mice bearing PDAC xenografts (Material
and Methods) (UNMC IACUC approval code: 18-177-01-FC). To model gemcitabine in
the clinic, mice were treated with gemcitabine at 640 mg/kg twice weekly, which is 80%
of the maximum tolerated dose. The Romidepsin/ACY-1215 combination had a mild
inhibitory effect on the growth of Capan-1 xenografts (Figure 28). Although gemcitabine
was initially able to inhibit tumor growth in this model, the effect was temporary, and
tumor growth resumed as a resistant population of cells grew out. Notably, treatment
with gemcitabine in combination with Romidepsin and ACY-1215 markedly inhibited this
later growth of tumors, leading to a statistically significant reduction in tumor size by 24
days compared with gemcitabine treatment alone. Thus, consistent with the in vitro
data, selective HDAC1, 2, and 6 inhibitors are able to potentiate the effects of
gemcitabine on PDAC tumors in vivo, blocking the ability of these tumors to grow
following prolonged gemcitabine treatment.
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Studies of Panobinostat in Combination with the Survivin
Transcriptional Repressor YM155
Note: Shane Laschanzky was initially under the supervision of Dr. Michael G.
Brattain. From 2014 until Dr. Brattain’s death in February 2016, he performed studies on
the combination of HDAC inhibition and transcriptional repression of survivin as an
approach for cancer therapy. The results of these studies are summarized below.

The Inhibitor of Apoptosis Protein (IAP), survivin, is unique in that it is the
smallest IAP and has not been demonstrated to bind caspase directly. Instead, survivin
exerts its anti-apoptotic activity by binding to XIAP, also an IAP, and inhibiting its
ubiquitin-induced degradation [168]. Survivin expression in PDAC is a negative
prognostic marker and is associated with more advanced disease [169]. Previous work
in the Brattain laboratory demonstrated a relationship between pan-HDAC inhibition and
re-expression of Transforming Growth Factor Beta Receptor 2 (TGFβ-R2), leading to a
reduction in survivin protein levels and an increase in apoptosis in colon cancer cell lines
[170]. Unpublished work in colon cancer models demonstrated a synergistic relationship
between YM155, a survivin transcriptional repressor, and the pan-HDAC inhibitor,
Belinostat. Given that TGFβ signaling is disrupted in over 50% of PDAC tumors [171],
we hypothesized that the survivin transcriptional repressor, YM155, would also
synergize with the pan-HDAC inhibitor panobinostat in PDAC cell models.
YM155, an imidazolium-based small molecule inhibitor, has demonstrated high
selectivity against survivin at the core gene promotor level [172]. Published work from
the Brattain laboratory showed that YM155 treatment reduces survivin mRNA
expression in both colon and PDAC cell models [173]. Thus, a combination of YM155
and panobinostat would be expected to target survivin expression via two independent
pathways, potentially decreasing the emergence of resistance mechanisms.
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Initial results were promising. Western blot analysis revealed a reduction in both
XIAP and survivin protein expression in MiaPaCa2 cells after 24 h exposure to
Panobinostat (Figure 29). However, follow-up studies failed to demonstrate a reduction
in survivin protein with the combination of YM155 and Panobinostat (Figure 30).
Instead, survivin protein levels appeared to increase with higher doses of Panobinostat
and with the combination of YM155 and Panobinostat at levels which individually would
reduce survivin protein expression (Figure 30). Given these disappointing results, the
change in supervisor, and our inability to obtain YM155 from Astellas Pharma, Inc., the
survivin pan-HDACi studies were discontinued.
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Utilizing Novel Multi-Target Small Molecule Inhibitors in
Combination with HDACi and Gemcitabine
Three experimental compounds designed by the Donald Durden group and
SignalRX (University of California, San Diego) were provided to our laboratory for
evaluation in PDAC cell lines, and to determine synergistic potential utilizing our
combinatorial methodology. The three compounds: SRX3225, SRX3177 and SF2523,
were characterized in PDAC cell lines for individual EC50 values, protein targets, and
combination potential.
The first compound evaluated, SRX-3225, is a first-in-class triple inhibitor of PI3K
(isoforms: p110α, p110ү, and p110δ), BRD4-1/2, and, HDAC6 [174]. Western blot
analysis for acetyl-α-tubulin confirmed that SRX-3225 is an HDAC6 inhibitor in PDAC
(Figure 31). However, this drug demonstrated no toxicity in PDAC cell lines at
concentrations up to 20 mM (data not shown). Further studies with SRX-3225 were not
conducted.
The second compound, SRX-3177, is another triple action inhibitor with activity
against BET, PI3Kα, PI3Kү, PI3Kδ, and CDK4/6 (Durden et al., unpublished). SRX3177 was developed to target these molecules in silico, utilizing proprietary “CRIMP”
technology with the intent of creating synthetic lethality by targeting tumor cell growth
signaling [174, 175]. Initial characterization by MTT assay revealed SRX-3177 to be
effective in the mid nanomolar range (Table 14).
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Published studies have demonstrated BET inhibitors to synergize with
Romidepsin in both cutaneous T-cell lymphoma [176] and urothelial carcinoma models
[177]. Given these published results, we tested the combination of SRX-3177 and
Romidepsin in PDAC cell lines. The initial SRX-3177/Romidepsin combination trials did
not demonstrate significant synergy in four of the five PDAC cell lines tested, with only
the Panc1 cells demonstrating any significant synergy (Figure 32). This avenue was not
further explored.
SF-2523, or Morpholinothienopyrane, is the most well characterized compound
provided to us by the Durden laboratory. SF-2523 is a dual inhibitor of PI-3K (p110α,
p110ү, and p110δ) and BRD4. Combined inhibition of PI3K and BRD4 proteins
effectively blocks MYC expression and activation, while also promoting MYC
degradation in cell line and animal models of neuroblastoma [178]. To determine if SF2523 would be a good candidate drug for PDAC therapy, we evaluated its effects in five
human PDAC cell lines and were able to demonstrate reduced viability in MTT assays
(Table 14). SF-2523 demonstrated toxicity in the low micromolar range in all PDAC cell
lines tested (Table 14). Initial studies into SF-2523’s activity in PDAC using Western
blot analysis demonstrated a marked reduction in pAKT (S473) levels by 30 minutes,
confirming strong inhibition of PI3K activity (Figure 33). Given SF-2523’s promising
results as a candidate for PDAC treatment, we tested it’s effects in combination with
gemcitabine as a basis for justification of future clinical trials. SF-2523 demonstrated
synergy with gemcitabine in the three PDAC cell lines tested at ED90 and in two of the
three cell lines at ED75 (Table 15).
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Discussion
Introduction
Chemotherapy is the use of drugs to destroy cancer cells. Chemotherapeutic
drugs target tumor cell growth, survival, and metastasis. Tumors acquire their growth
advantage, ability to avoid apoptosis and metastatic potential via dysregulation of genes
and signaling pathways. Importantly, these advantages come at a cost, creating
vulnerabilities that can be exploited. An example of inherent vulnerability in tumor cells
is their susceptibility to HDACi (as discussed in Chapter 2, tumor cells are up to ten
times more susceptible to HDACi over non-transformed cells). The focus of this work
has been to elucidate the most effective way to utilize HDACi drugs to target PDAC cells
while minimizing toxicity.
Although pan-HDACi have demonstrated potential in solid tumors, including
PDAC, significant dose limiting toxicities have prevented their use in the clinic [179]. It
has been proposed that the dose limiting toxicities associated with pan-HDACi may be
avoided through targeted HDAC inhibition. This notion has led to the development of
targeted HDACi for the treatment of multiple cancers including PDAC [180]. However,
as discussed in Chapter 2 of this work, the success of this strategy has been limited to
date.
The studies described in this dissertation were based on the concept that a better
understanding of the specific HDAC(s) required for maintenance and progression of
PDAC, combined with the use of more selective inhibitors targeting these HDAC(s),
would provide improved therapeutic benefit while minimizing off-target toxicity to normal
cells. Little is known regarding the role of the 11 classical HDAC proteins in PDAC
development and maintenance. As explored in Chapter 1, although there is some
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redundancy between HDAC proteins within each HDAC class, there is little to no
redundancy between HDACs of different classes. HDAC proteins can also be
ubiquitously expressed or cell-type specific (given the diversity of HDAC proteins in
normal cells, we hypothesized that the HDAC protein repertoire of PDAC is likely to be
highly specific). Targeted inhibition of HDACs expressed in PDAC was, therefore, used
to identify HDACs that are essential for PDAC survival as well as HDACs whose
disruption may lead to off-target toxicities. The uncoupling of efficacy from dose limiting
toxicity was the ultimate rationale for this work.
A major treatment advantage associated with HDACi is related to their ability to
work synergistically with traditional chemotherapies such as gemcitabine, and to reverse
acquired drug resistance (Chapter 2). The ability of HDACi to work synergistically with
gemcitabine provided another avenue to explore, both as a novel way to increase
gemcitabine’s efficacy but also to reduce off-target effects and toxicities by reducing
gemcitabine’s effective dose. In the context of this work, for selective HDAC inhibitors to
have clinical potential, they must meet three criteria: significantly less off-target effects
and toxicities in comparison to pan-HDACi, at least comparable efficacy to that of panHDACi, and the ability to work synergistically with gemcitabine.

Moving the Field Forward
Over the past decade, a number of phase I clinical studies of pan-HDACi in
combination with traditional chemotherapies have been performed in solid tumors,
including PDAC [88, 181-183]. This strategy has not yielded beneficial results, largely
because of significant off-target cardiac toxicities associated with pan-HDACi treatment.
However, despite the failure of pan-HDACi treatment for solid tumors in the clinic,
exploration of the potential of new pan-HDACi drugs is ongoing and there is continued
interest in bringing these agents to clinical trial as quickly as possible [184, 185]. The
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experiments presented were designed to help move the field forward by demonstrating
the potential of an attractive alternative: the use of tailored HDAC inhibition utilizing
HDAC isoform-specific inhibitory drugs.
Many of the off-target cardiac toxicities associated with pan-HDACi can be
attributed to inhibition of the class IIa HDACs 4, 5, 7, and/or 9. Class IIa HDACs are
significantly more tissue-specific and have been implicated in off-target effects of the
pan-HDACis such as heart arrythmia [186]. Interestingly, two recent studies utilizing the
HDAC1, 2, and 3 inhibitors Mocetinostat or Tacedinaline in combination with
gemcitabine for the treatment of patients with advanced PDAC have come to a similar
conclusion as our study; HDAC1, 2, and 3 inhibitors in combination with gemcitabine
yield no advantage over each drug alone [187, 188] (Figure 10). In contrast, a
combination study in PDAC cell lines utilizing CG200745 or Chidamide has yielded
promising results. Chidamide, an HDAC1/2/3/6/10 inhibitor currently in phase II trials for
peripheral T-cell lymphoma [189], demonstrated synergistic effects with gemcitabine in
BxPc3 and CFPAC PDAC cells as well as in BxPc3 mouse xenograft models [52].
Based on our work, it can be inferred that the basis for the failure of Mocetinostat and
Tacedinaline and of the success of Chidamide was in their differential ability to inhibit
HDAC6. However, based on past knowledge, patients treated with Chidamide at levels
high enough to affect solid tumors such as PDAC, will most likely experience significant
negative off-target effects, including cardiac toxicities (due to inhibition of HDAC3 by
Chinamide and subsequent induced loss of function of HDAC 4, 5, 7 and 9) (Figure 1).
Since HDAC3 provides the deacetylase activity for the class IIa enzymes,
inhibition of HDAC3 directly affects the activity of the class IIa enzymes (HDACs
4/5/7/9). Given the critical importance of HDAC3 to the activity of the class IIa HDACs,
any inhibitor targeting HDAC3 (such as Chidamide) should be considered an
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HDAC3/4/5/7/9 inhibitor. This becomes important when factoring in the mitigating
abilities of specific-HDACi in comparison to pan-HDACi in relation to off-target toxicities.
The distinction between selective and pan-HDACi must be clearly delineated to avoid
the significant side effects that restrict pan-HDACi from use clinically. For example, the
HDAC1,2,3,6,10 inhibitor Chidamide is presented as a novel class I and IIb inhibitor.
However, in reality, Chidamide is a class I and II inhibitor with the ability to inhibit 9 of the
11 classical HDACs. Given its comprehensive inhibitory profile, clinical side effects
similar to pan-HDACi are expected.
Evidence from this work and others suggests that inhibition of HDAC3 without
inhibition of HDAC6 abrogates the synergistic effects of HDACi in combination with
gemcitabine. Consistent with this notion, while the HDAC1/2 inhibitor Romidepsin
effectively synergizes with gemcitabine (Figure 24 and [190]), the combination of the
HDAC1/2/3 inhibitor Mocetinostat and gemcitabine is antagonistic, an effect that can be
reversed with the addition of an HDAC6 inhibitor such as LMK-235 or ACY-1215 (Figure
2i, Table 12ii). This phenomenon is also apparent in the ability of pan-HDACi such as
Panobinostat, Belinostat, or Vorinostat to synergize with gemcitabine in PDAC cell
models [55, 88, 191].
Our study not only demonstrates the expendability of HDAC3 inhibition for
effective PDAC therapy, but also presents a strong case for HDAC3 as being
responsible for a loss, or at least significant reduction, in synergy with gemcitabine.
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Evidence for a Critical Role of Combined HDAC1, 2, and 6
Inhibition for Achieving HDACi Success in PDAC
Our study indicates that inhibition of HDACs 1, 2, and 6 opens a therapeutic
window in which lower effective doses of both HDAC inhibitors and traditional
chemotherapeutics such as gemcitabine will be effective.
Although we did not fully explore the mechanisms behind the promising effects of
HDAC1, 2, and 6 inhibition in combination with gemcitabine in PDAC, the cooperativity
between HDAC1, 2, and 6 inhibition is not unexpected. Several explanations for this
cooperativity can be found in the literature. Firstly, HDAC1 is overexpressed in 40% of
PDACs and has been associated with a significantly worse prognosis [192, 193].
Similarly, HDAC2, a well-established tumor promoter, is also overexpressed in a majority
of PDACs [193]. Given the reported ability of HDAC1 to compensate for HDAC2 loss
[155], a need for simultaneous inhibition of these two enzymes is expected. HDACs 1
and 2 may also play a role in epithelial to mesenchymal transition given that they have
been reported to downregulate E-cadherin in PDAC cells [194]. E-cadherin loss has
also been attributed to resistance to gemcitabine [195], providing a possible explanation
for inhibition of HDACs 1 and 2 as critical to the HDACi/gemcitabine synergy observed in
our study.
The connection between HDAC2 and HDAC6 is also well established in the
literature. Interactions between HDAC2 and 6 have been implicated in loss of the
primary cilium during PDAC tumorigenesis through a mechanism that involves HDAC2mediated upregulation of Aurora A and subsequent increased phosphorylation/activation
of HDAC6 [196].
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Recent progress in understanding the role of the oncogenic properties of mutant
p53 [197] has provided another explanation for the success of simultaneous HDAC1, 2,
and 6 inhibition in PDAC. HDAC6 inhibition selectively destabilizes mutant p53 protein
while promoting the acetylation and activity of wild-type p53 [198, 199]. HDAC1 and 2
inhibition, in turn, downregulates both mutant and wild-type p53 at the transcriptional
level [200]. Given that, as previously stated, p53 is mutated in over 75% of PDAC
tumors, simultaneous inhibition of HDAC1, 2, and 6 leading to maximum silencing of p53
signaling should yield significant anti-tumor effects. Interestingly, our experiments with
Panobinostat clearly demonstrate this phenomenon. In Figure 7, Western blot analysis
clearly shows that Panobinostat treatment reduces p53 expression in PDAC cells.
While inhibition of HDACs 1, 2, and 6 is important for the treatment of PDAC, of
equal importance is the protection of the remaining 8 classical HDACs. As previously
stated, pan-HDACi have not been further developed for the clinical management of solid
tumors due to significant off-target effects. By targeting HDAC1, 2, and 6 specifically,
we have created a drug regimen which provides the anti-tumor effects of pan-HDACi
and the synergistic effects of pan-HDACi with gemcitabine, while preventing off-target
toxicities associated with pan-HDACi.

Alternate Combinatorial Strategies to Reduce the Effective Dose
of Pan-HDACi and Minimize Off-Target Effects
In 2013, at the onset of this study, many of the studies exploring selective HDACi
in synergistic combinatorial treatment with traditional chemotherapies had not been
published or were not yet well known. The dominant strategy for bringing HDACi to the
clinic for the treatment of solid tumors was to reduce the effective dose of pan-HDACi
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through combination with a small molecule inhibitor targeting a relevant signaling
pathway. Given the success of pan-HDACi in hematopoietic malignancies such as T-cell
lymphoma [201] and multiple myeloma [202], it was hypothesized that the key to
success in solid tumors was to shift the effective dose in solid tumors closer to that in
hematological tumors. Multiple studies utilizing small molecule inhibitors targeting
different signaling pathways related to HDACi were designed and tested [203, 204].
In the same vein as these efforts, our study was originally designed to combine
the small molecule inhibitor of survivin transcription, YM155, with the pan-HDACi,
Panobinostat for the eventual triple combination with gemcitabine in a clinical trial. As
stated previously, the death of Dr. Michael Brattain, compounded with an unexplained
increase in survivin expression in response to Panobinostat or Panobinostat/YM155
combination treatment (Figure 30) and our inability to obtain YM-155 from Astellas,
prevented this work from moving forward.
The increase in survivin protein we observed with high doses of Panobinostat
may be explained by the inhibition of HDAC6. Survivin is not typically expressed in nondividing normal cells; however, it is expressed in nearly all human cancers [205]. In
normal cells, survivin acts as a regulator of mitosis. The protein is upregulated during
the G0/G1 phase of the cell cycle and inhibition or downregulation of survivin prevents
cell cycle progression into S-phase [206]. During normal development, survivin is
acetylated by CREB-binding protein and restricted to the nuclear compartment where it
cannot bind to XIAP and interfere with apoptosis [207]. In cancer, HDAC6 deacetylates
survivin allowing it to enter the cytoplasm and assume its anti-apoptotic role [208]. In
our Panobinostat/YM155 study, the observed increase in survivin may have reflected an
accumulation of nuclear protein. Cellular fractionation experiments and analysis of the
nuclear compartment for survivin could answer this question. Antibodies against ac-
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survivin(K129) could also be utilized in conjunction with cellular fractionation to further
establish this phenomenon as the explanation for the increase in survivin expression
observed in response to pan-HDACi treatment.
The use of the experimental compounds provided by Dr. Donald Durden
reinforced the need for a tailored approach to combination treatment, especially in the
context of HDACi. The HDAC6/BRD4/PI3K inhibitor SRX3225 demonstrated no toxicity
when tested on our panel of PDAC cell lines. This result is in contrast to published
literature demonstrating a strong synergistic relationship in PDAC between JQ1 (a BRD4
inhibitor) with SAHA (a pan-HDACi) [209].
Given the adverse effects associated with pan-HDACi in the clinic, if the
BRD4/HDAC combination is to be further explored in PDAC, specific inhibition should be
employed. This work provides a template for that study. Investigators following our
methodology could substitute JQ1, or any other BRD4 inhibitor, for gemcitabine and
conduct selective HDAC inhibition and siRNA knockdown studies.
Taken together, the compounds provided by Dr. Durden failed to support the
Bromodomian and Extraterminal Domain (BET) proteins as targets for PDAC toxicity.
The BET protein BRD4 is targeted by each of the three drugs tested in our PDAC panel,
with very diverse results ranging from no toxicity to significant toxicity in these cells. The
BET proteins are epigenetic readers which are reported to be the link between
acetylated transcription factors and histones, for the activation of RNA polymerase II
[210]. The idea behind the combination of a BET inhibitor with a PI3K inhibitor and/or a
CDK4/6 inhibitor is to prevent epigenetic changes associated with acquired drug
resistance. In our study of SF2523, a reasonable ED50 value was obtained in all five cell
lines indicating PDAC toxicity (Table 14). Effects of the second-generation drug
SRX3177, which also targets CDK4/6 (Table 14) were even more promising.
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Studies have identified CDK4/6 inhibitors as powerful anti-neoplastic drugs [211],
whose effects are rapidly bypassed by other signaling mechanisms such as PI3K/AKT
signaling [212, 213]. SRX3177 was designed to address potential drug-induced
resistance mechanism via inhibition of epigenetic signaling networks activated by the
tumor though BET inhibition and blockade of the PI3K signaling pathway. Consistent
with our findings with SRX3225 in PDAC cell lines, the combination of Romidepsin with
SRX3177 did not produce significant synergy. Taken together, these results suggest
that HDAC inhibition is not a necessary or beneficial addition to CDK4/6/BET/PI3K
combinatorial strategies.

Conclusions and Future Directions
The overarching question that drove the experiments performed in this study
was; Could a rational reduction in the number and type of HDACs targeted by HDACi be
the key to unlocking their potential in the clinic? Our work shows some promise in
achieving this goal.
Multiple studies and clinical trials mentioned previously in this work have shown
that pan-HDAC inhibitors such as Panobinostat can be highly effective in managing
PDAC tumors. However, these drugs have never been utilized successfully in the clinic
due to off-target toxicities. The off-target toxicities are frequently attributed to the higher
doses required for efficacy in solid tumors.
At the onset of this work, few studies had addressed the potential of using
combinations of selective HDACi to identify specific activities of HDACs in tumors and
design novel therapeutic strategies with reduced off-target effects. Over the years it took
to complete this work, however, multiple studies were published utilizing more specific
HDACi with successful results [52, 53]. What sets our work apart from other comparable
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contemporary studies is the in-depth approach used to identify HDACs of interest.
Class-specific small molecule inhibitors were used alone and in combination and effects
were further explored using siRNA-mediated knockdown of relevant HDAC(s). Results
were fully established using a combination of HDAC-specific small molecule inhibitors
and HDAC knockdown strategies. This work provides a roadmap for other scientists to
follow, not only as a formula for the development and utilization of more advanced
HDAC targeting drugs but also as a general strategy for elucidating HDACs of interest in
the context of tumor sequencing and personalized medicine.
Further studies are needed to determine the mechanism of HDAC1, 2, and 6
inhibition both in relation to anti-tumor effects in PDAC, but also to the synergy with
gemcitabine. Determination of the underlying cellular pathways responsible for the
observed benefits of HDAC1, 2, and 6 inhibition with gemcitabine may yield new insights
which could lead to an even more potent and effective drug combination. To futher
explore the activity of HDAC1, 2, and 6 in combination with gemcitabine, genetic rescue
experiments should be performed in addition to the KD experiments presented in this
work. For example, to confirm the results obtained in Figure 20 (HDAC1, 2, and 6 KD in
combination with gemcitabine), re-expression of the target HDACs leading to an
increase in the effective dose of gemcitabine (to levels comparable with the non-target
control group) would reinforce HDACs 1, 2, and 6 as the proteins responsible for the
observed synergy.
Additional animal studies are also required to determine if selective inhibition of
HDACs 1, 2, and 6 in combination with gemcitabine influences metastasis, or if it has an
ability to prolong survival. Successful pancreatic orthotopic studies, as well as studies
with the KRAS mouse model would justify human PDX tumor studies and eventually
clinical trials.
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Summary
The HDACs are an ancient and evolutionarily conserved family of proteins,
predating the histones themselves. Eukaryotes have co-evolved with naturally occurring
HDACi, developing pathways to overcome the effects of these substances, pathways
that are frequently lost in cancers such as PDAC. Given the immense potential of
HDACi in the treatment of cancer, approaches must be developed to implement the use
of these drugs in the clinic. Tailoring specific HDAC inhibitory combinations to PDAC
provides an avenue to decrease the effective dose of these drugs and concurrently
alleviate their toxicity. In a disease such as PDAC, where curative surgery is rarely an
option and chemotherapeutics offer the only hope for disease management, successful
utilization of HDACi offers a chance to prolong life with minimal negative side effects.
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Materials and Methods
Cell Culture
Human PDAC cell lines, MiaPaCa-2 (ATCC CRL-1420), Capan-1 (ATCC HTB79), BxPC-3 (ATCC CRL-1867), CFPAC-1 (ATCC CRL-1918), T3M-4 (Riken RCB1021),
and PANC-1 (ATCC CRL-1469) were maintained in McCoy’s 5A medium supplemented
with pyruvate, vitamins, amino acids, antibiotics, and 10% fetal bovine serum at 37 ºC in
5% CO2. Where indicated, cells were treated with Panobinostat (Sellechem, Houston,
TX, USA), Droxinostat (Sellechem), Mocetinostat (Sellechem), LMK-235 (Sellechem),
ACY-1215 (MedChem Express, Monmouth Junction, NJ, USA), Romidepsin (MedChem
Express), and/or gemcitabine (Sagent Pharmaceuticals, Schaumburg, IL, USA) in
DMSO (Sigma, St. Louis, MO) (except gemcitabine, which was in sterile water). For
controls, cells were treated with vehicle; DMSO concentrations in the final culture
medium were ≤ 0.001%.

Western Blot Analysis
Cells were lysed in 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1% Nonidet P-40, 2
mM EDTA, 0.1% SDS, 50 mM NaF, 10 mM Na3V04, 1 mM phenylmethylsulfonyl
fluoride, 25 µg/mL β-glycerophosphate, and one protease inhibitor tablet
(Complete Protease Inhibitor Cocktail, Roche, Tuscon, AZ, USA, Cat: 11697498001)
and extracts (30 µg protein) were analyzed by Western blotting as described. Protein
concentration was determined by Pierce BCA Protein Assay Kit (Thermo Fisher
Waltham, MA, USA, Cat: 23225). Protein separation and transfer was performed with
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the BioRad Mini-Cell tank and powerpack equipment (BioRad, Hercules, CA, USA).
After lysis and protein extraction, a 15 µL aliquot containing 30 µg of protein and loading
buffer (BioRad) was loaded into each well of either 12% or 15% gels poured in-house
(BioRad) and run at 100 V until the blue loading buffer line reached the bottom of the
gel-plate. Proteins were then transferred to “Amersham” nitrocellulose blotting
membrane (0.45 µM pore size) (GE Healthcare, Incheon, South Korea, Cat: 10600023)
via a 90 min transfer at 500 mA on ice. Following blocking with 5% milk in TBST, blots
were incubated with one of the following primary antibodies from Cell Signaling: [PARP:
95425; Caspase 7: 128275; GAPDH: 5174; HDAC1: 3565; HDAC2: 51135; HDAC3:
39495; HDAC4: 7628; HDAC5: 204585; HDAC6: 76125; acetyl-α-tubulin (Lys40): 5335;
acetyl-histone 3: 9649; cleaved caspase 3: 9664]. Following transfer, membranes were
cut (guided by molecular weight markers) to facilitate probing for multiple proteins at
specific molecular weights.

MTT Assays
Initially, PDAC cells were plated in 96-well cell culture plates (Thermo Fisher
Scientific, Waltham, MA, USA) at densities ranging from 100-1000 cells/well to establish
cell line-specific growth curves. Cells were then plated at densities consistent with the
logarithmic growth phase occurring concurrently with drug treatments (100 cells/well Capan1, 250 cells/well - MiaPaCa2 and BxPc3, 500 cells/well – CFPAC and Panc1).
Twenty-four hours after initial plating, cell medium was replaced, and drugs or
vehicle were administered. Cells were then allowed to grow for 72 h. After the 72-h
drug treatment, MTT assays were performed. The assays consisted of addition of 50 µL
of 3-(4,5 Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT Reagent) (Sigma)
and incubation for 2 hours at 37 °C. Next, the MTT reagent was aspirated and replaced
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with 100 µL DMSO (Sigma) and the plates were analyzed via optical density at 570 nm
using the ELx808™ Absorbance Microplate Reader (BioTek, Winooski, VT, USA).
Results were interpreted via GraphPad analytical software (GraphPad Software, San
Diego, CA, USA).

siRNA Knockdown
Human ON-TARGETplus SMARTpool siRNAs against HDACs 1, 2, 3, 4, 5, and 6
and non-targeting siRNA were purchased from Dharmacon (HDAC 1: L-003493-000005, HDAC 2: L-003495-02-0005, HDAC 3: L-003496-00-0005, HDAC 4: L-003497-000005, HDAC 5: L-003498-00-0005, HDAC 6: L-003499-00-0005, Non-Target: D-00181001-50) . ON-TARGETplus SMARTPool siRNAs consist of four siRNAs that are designed
and modified to increase specificity and reduce off-target effects. MiaPaCa-2 and
Capan-1 human PDAC cells were transfected with 37.5 pmol each of targeted and nontargeting siRNA using Lipofectamine 3000 (Thermo Fisher Scientific, Cat: L3000015)
according to the manufacturer’s protocol. After 48 h, cells were analyzed by Western
blotting or subjected to drug treatment and MTT assay.

Cell Cycle Analysis
CFPAC cells were plated in 6-well culture dishes (Falcon/Corning, Tewksburry,
MA, USA) at 500k cells/well and allowed to grow for 48 h. Next, the cells were treated
with either drug or DMSO control at 0.001% for 24 h. Nocodazole-treated cells were
exposed to 1 µM Nocodazole (Sigma, Cat: M1404) in DMSO concurrently with HDAC
inhibitor exposure. 72 h after initial plating, cells were trypsinized utilizing the previously
reported cell culture methodology and reagents. Approximately 1 million cells were
transferred to 2 mL microcentrifuge tubes and pelleted via benchtop microcentrifuge at
10,000 g for 1 min at room temperature. The supernatant was decanted, and 1 mL
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ethanol was added dropwise to each tube under gentle vortexing. The cell/ethanol
mixture was then incubated at 4 ºC for 30 min followed by centrifugation as above.
Ethanol was decanted and cells were washed once with 1 mL PBS and again spun
down. Next, 1 mL of fresh Telford reagent (1.681 mg EDTA (Sigma), 1.34 mg RNAse A
at 93 U/mg (Sigma), 2.5 mg propidium iodide (Sigma), 50 mL Triton X-100 (Sigma)), and
50 mL PBS were added to each vial and allowed to incubate for 1 hour. After
incubation, cells were spun down, resuspended in 3 mL of PBS and filtered into 5 mL
flow cytometry tubes (Falcon) on ice. Cells were then analyzed via flow cytometry
immediately after filtration. Propidium iodide staining was performed in accordance with
the protocol suggested by the UNMC Flow Cytometry Facility and analysis was
performed under supervision of the Core Facility staff.

Annexin V-FITC Assay
MiaPaCa-2, Capan-1, and PANC-1 cells were plated at 2.5 X 105 in 10 cm
culture plates and treated with HDAC inhibitors and/or gemcitabine after 24 h. Following
30 h of drug treatment, apoptosis (cell surface phosphatidylserine) was assessed using
the Annexin V-FITC Apoptosis Detection Kit (Sigma, Cat: APOAF) as instructed by the
manufacturer. Flow cytometry was performed in the Flow Cytometry Core Facility at the
University of Nebraska Medical Center (UNMC).

Mouse Xenograft Studies
All animal experiments were performed under a protocol approved by the IACUC
at UNMC (approval code: 18-177-01-FC). Capan-1 cells (5 X 106) were injected into the
flanks of athymic NCr-nu/nu mice (Charles River, Durham, NC, USA). After tumors had
reached ~1000 mm3, 16 mice per group were treated with intraperitoneal injection of
either vehicle, 2 mg/kg Romidepsin plus 40 mg/kg ACY-1215, 640 mg/kg gemcitabine,
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or 2 mg/kg Romidepsin plus 40 mg/kg ACY-1215 plus 640 mg/kg gemcitabine for 3
weeks. Treatment schedules were as follows: 40 mg/kg ACY-1215, daily; 2 mg/kg
Romidepsin, twice weekly; 640 mg/kg gemcitabine, twice weekly. Tumors were
measured daily using calipers, and volumes were estimated using the formula 3.14/6 X
length X width2.

Analysis of Drug Interactions
Analysis of drug combination effects and combination index (CI) was performed
using the method of Chou and Talalay [214, 215]. Cell lines were treated with drugs
individually and in combination at equipotent ED50 ratios for each drug for 72 h, and CI
values were calculated from the results of MTT assays using Calcusyn software (Biosoft,
Cambridge, UK). CI > 1 indicates antagonism between drugs, CI = 1 indicates additive
effects, CI < 1 indicates drug synergy.

Statistics
Curve fitting and estimation of ED50 values for drug treatments were performed
using GraphPad Prism Software (GraphPad Software). Statistical differences were
determined by Student’s t test using Microsoft Excel (p < 0.05 was considered
statistically significant). For xenograft growth, descriptive statistics and mean plot
(counts, means, standard deviations, minimums, and maximums) were used to
summarize the tumor growth for treatment days and groups. Measurements of each
outcome observed over treatment days were considered as repeated measures and fit
with a linear mixed effect model with AR(1) structure for correlations to evaluate the
change of the outcome measurement values (tumor growth) between treatment groups.
In addition, pairwise comparisons of outcome measurements in treatment groups were
compared in each measurement time point and adjusted for multiple comparisons with
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Tukey’s method. Significance was determined by including interaction terms of
treatment day and group in the mixed effect models. All analyses were done using SAS,
Version 9.4 (SAS, Cary, NC, USA). p < 0.005 was considered statically significant.
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